Vascular Perfusion Solutions
Vascular Perfusion Solutions is developing the VP.S ENCORE®, a cardiac perfusion system designed to extend donor heart viability up to 8 hours.
Secondary Market Price
How Vascular Perfusion Solutions Measures Up
To help you manage your Vascular Perfusion Solutions equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Vascular Perfusion Solutions's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Vascular Perfusion Solutions Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Vascular Perfusion Solutions's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Vascular Perfusion Solutions, Inc. is a company focused on developing organ preservation technology. The company is currently developing the VP.S ENCORE®, a premarket cardiac perfusion system designed to extend the viability of donor hearts for up to eight hours. This system is portable, uses a blood-free perfusate, and features a fail-safe mode that reverts to cold static storage if perfusion is interrupted. The company is currently engaged in preclinical evaluation of the device.
Looking forward, Vascular Perfusion Solutions aims to complete its preclinical studies for the VP.S ENCORE® and subsequently seek regulatory approval for commercial use. The device has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), a status granted to expedite the development and review of devices for serious conditions. The company's stated objective is to provide organ transplant teams with technology that addresses limitations such as time and distance, with the goal of increasing the number of transplantable organs.
- Children's Hospital of Orange County
- Children's Wisconsin
- Phoenix Children's Hospital
- Texas Children's Hospital
- University of Houston
- Rice University
- Baylor College of Medicine
- Co-Founder, Co-Founder Tom DeBrooke
- Co-Founder, Co-Founder Leonid Bunegin
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Vascular Perfusion Solutions worth joining?
Evaluating a job offer from a startup requires analyzing the potential of its equity package. Using a platform like Prospect can help you model the potential value of your equity and compare the opportunity against other companies.
What should I do with my Vascular Perfusion Solutions stock?
Managing private company stock involves creating a strategy for exercising options and selling shares to maximize your returns. Prospect builds personalized, multi-year strategies to help you decide when to act and how to minimize your tax burden.
Can you sell Vascular Perfusion Solutions stock?
As a private company, Vascular Perfusion Solutions stock isn't traded on a public exchange, but you can often sell shares through secondary markets or company-approved tender offers. Tools are available to help you navigate these sales and determine which shares are most tax-optimal to sell.
How can I find the value of my Vascular Perfusion Solutions stock?
Since the company is private, its stock value is not publicly available, but you can get a data-driven estimate. Prospect uses machine learning models that analyze funding rounds, market data, and other signals to project your equity's potential value.
What is Vascular Perfusion Solutions's equity worth?
The precise worth of private equity is uncertain until a liquidity event like an IPO, but you can work with a probable range of outcomes. Financial modeling platforms can project the most likely value of your Vascular Perfusion Solutions equity based on proprietary data.
What is Vascular Perfusion Solutions's stock ticker symbol?
As a privately held company, Vascular Perfusion Solutions does not have a stock ticker symbol. Ticker symbols are only assigned to companies that are listed and traded on a public stock exchange.
Can I buy or sell Vascular Perfusion Solutions stock?
Buying stock in a private company is typically restricted to accredited investors during specific funding rounds. Selling is often possible during liquidity events like tender offers, and platforms like Prospect offer tools to help employees manage these sales.
What is the criteria to buy or invest in Vascular Perfusion Solutions stock?
While direct investment is usually limited, you can evaluate the company using the same criteria as venture capitalists, such as its funding history, market traction, and growth metrics. Prospect's platform provides this VC-grade analysis to help you understand your equity's potential.
